Search

El extraordinario desarrollo de los estudios sobre las escrituras del viaje ha ido ampliando las investigaciones con las más variadas categorías de viajeros. Pero todavía no se aprecia una atención especialmente dirigida hacia los numerosos textos cuyos protagonistas son niños que por distintas razones, deben alejarse del hogar. Sin embargo, muchas de estas narraciones ocupan lugares destacados en el canon de diversas literaturas o, por lo menos, han aportado arquetipos insoslayables a la historia de la cultura. En el presente trabajo, se revisan ejemplos donde los «héroes» son viajeros de corta edad, se analizan los modelos narrativos que han persistido durante siglos, las transformaciones que los han ido adaptando a diferentes coordenadas históricas y la irrupción de nuevos motivos y prácticas discursivas en la transición de la modernidad a la postmodernidad. En el abordaje de cada contexto cultural —de la Edad Media hasta la sociedad actual del espectáculo—, se ha tenido en cuenta la concepción predominante de la infancia y sus relaciones con aspectos que exceden esa etapa para actuar como reflejo de cuestiones del mundo adulto.

La presente antología comentada se inscribe en un proceso continuado de investigación que llevó a la autora, ya en 1960, a publicar Cantares históricos de la tradición argentina. Hay que congratularse de que una buena parte del material contenido en aquella obra, hace tiempo agotada, vuelva a estar a disposición de los lectores a través del libro que nos ocupa. La fuente principal del trabajo está constituida por la “Colección de Folklore”, realizada por el Consejo Nacional de Educación con los aportes de los maestros de las escuelas Ley Láinez de todo el país, que habían respondido a la Encuesta Folklórica General del Magisterio, realizada en 1921. Dicha encuesta se basó en los métodos reconocidos en Europa en aquellos momentos y se llevó a cabo sobre cuestionarios inspirados en la clasificación del folklore del especialista francés Paul Sébillot.

Copyright of Letras (0326-3363) is the property of Pontificia Universidad Catolica Argentina and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Letras (0326-3363) is the property of Pontificia Universidad Catolica Argentina and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Letras (0326-3363) is the property of Pontificia Universidad Catolica Argentina and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: Real-world data for patients with endometrial cancer (EC) are limited, particularly in Latin America. We present treatment pattern findings from ECHOS-A - Endometrial Cancer Health Outcomes Study in Argentina., Materials and Methods: A retrospective study using clinical data from privately insured patients with EC diagnosed from 2010 to 2019. Index (diagnosis proxy) was first date of an EC-related health term or treatment. Demographics, clinical characteristics, and FIGO staging were described. Disease progression and survival were assessed until study end, loss to follow-up, or death., Results: Of 805 patients with EC, 77.4 % (n = 623/805) received any treatment and 22.6 % (n = 182/805) received none. Among those treated, 31.8 % (n = 198/623) had first-line (1L) systemic therapy, and 45.5 % (n = 90/198) proceeded to second-line (2L) therapy. Mean follow-up was 33.6 (SD 31.8) months. Of those receiving any treatment, 87.3 % (n = 544/623) had FIGO stage data (I, 62.9 %; II, 18.6 %; III, 13.6 %; IV, 5.0 %). Treatment by class in 1L and 2L, respectively, were platinum chemotherapy, 73.7 %, 36.7 %; non-platinum chemotherapy, 73.7 %, 62.2 %; immunotherapy, 1.0 %, 11.1 %; hormone therapy, 17.7 %, 26.7 %. Carboplatin/paclitaxel was the most frequent 1L (52.5 %) and 2L (14.4 %) regimen. Mean time to progression was 14.1 (SD 16.3) and 8.8 (SD 8.3) months in 1L and 2L, respectively. Adjusted 1- to 5-year risk of progression/death was 46.5-77.5 % and 65.0-86.2 % in 1L and 2L, respectively., Conclusions: Approximately one-quarter of patients with EC received no treatment, and approximately two-thirds were not treated with 1L systemic therapy. Efforts to better understand the reasons for these treatment patterns are crucial for improving patient outcomes., Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: CS, PM, MC, and LJ are employees of and hold financial equities in GSK. GA, JQ, and TLNS are complementary employees of and do not hold financial equities in GSK. MCR reports receiving speaker fees and/or congress attendance support from AstraZeneca, GSK, and Roche. PS, NES, VAS, DO, and FC have no conflicts of interest to declare., (© 2024 The Authors.)

Aim: To evaluate real-world data on treatment patterns in Argentina and Brazil in patients with ovarian cancer. Methods: This study evaluated de-identified antineoplastic exposure data from a private healthcare provider in Argentina and health claims database (Orizon) in Brazil from 2010 to 2019 and 2015 to 2020, respectively. Results: Platinum-based chemotherapy was the most common first-line therapy (Argentina: n =311 [87.6%]; Brazil: n = 1142 [79.3%]). The proportion of patients receiving platinum-based chemotherapy declined across both populations from first- to second-line, while use of non-platinum-based, targeted, and hormone therapies increased. Duration of platinum-based treatment and time to next treatment decreased from first- to fourth-line. Conclusion: There is an unmet need for effective therapies that can prolong time to next treatment in ovarian cancer in Argentina and Brazil.

We introduce sequential analysis in quantum information processing, by focusing on the fundamental task of quantum hypothesis testing. In particular, our goal is to discriminate between two arbitrary quantum states with a prescribed error threshold ε when copies of the states can be required on demand. We obtain ultimate lower bounds on the average number of copies needed to accomplish the task. We give a block-sampling strategy that allows us to achieve the lower bound for some classes of states. The bound is optimal in both the symmetric as well as the asymmetric setting in the sense that it requires the least mean number of copies out of all other procedures, including the ones that fix the number of copies ahead of time. For qubit states we derive explicit expressions for the minimum average number of copies and show that a sequential strategy based on fixed local measurements outperforms the best collective measurement on a predetermined number of copies. Whereas for general states the number of copies increases as log1/ε, for pure states sequential strategies require a finite average number of samples even in the case of perfect discrimination, i.e., ε=0.

Introduction and Objectives: Vismodegib (Erivedge ® ), a hedgehog pathway inhibitor, is approved to treat metastatic or locally advanced basal cell carcinoma (BCC) not suitable for surgery or radiotherapy. Our main objectives were to study the objective response rate (ORR) assessed by treating physicians and safety of vismodegib in a real-world practice setting in Argentina., Material and Methods: This is a prospective cohort study in real-world practice. We included consecutive adult patients treated in Argentina with locally advanced or metastatic BCC not suitable for surgery or radiotherapy. Patients were followed until the end of the study, death, or loss to follow-up, whichever occurred first. Patients received 150 mg vismodegib PO daily., Result: We included in the analysis 63 patients who received treatment. Locally advanced BCC was present in 57 (90.4%) and metastatic disease in two (3.2%). ORR was observed in 46 patients (73%; 95% CI: 60.3-83.4), with partial response in 36 (57%; 95% CI: 44-69.5) and complete response in 10 (16%; 95% CI: 7.8-27.2). As to safety, 48 (76.2%) patients had at least one adverse event (AE). The most frequently observed AEs were muscular spasms in 25 (39.6%); dysgeusia in 23 (36.5%); alopecia in nine (14.2%); weight loss in seven (11.1%); and ageusia in (9.5%) patients. Serious AEs were observed in 11 (17%) patients with one episode of deep vein thrombosis and pulmonary embolism resulting in death., Conclusion: Our study provides additional evidence of the efficacy and tolerability of vismodegib in patients with locally advanced or metastatic BCC in a real-world practice., (© 2020 The International Society of Dermatology.)

We investigated the possibility of enhancing the adherence capacity of four low-adherent Arcobacter butzleri strains after serial intraperitoneal passage (i.p.) in mice. All the strains enhanced their adherence capacity after the first passage, increasing their adhesion rates after each passage. These results suggest that i.p. passage enhances the expression of adherence in A. butzleri strains.

We studied three pregnant women with acute chagasic infection. Two patients, infected in the third trimester of pregnancy, had uninfected children. The third patient, infected earlier, had an infected newborn. These results encourage research on risk factors of transmission and on medical decisions concerning pregnant women with acute Chagas' disease.